Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30022203HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022204HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022205HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022206HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022207HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022208HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022209HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022210HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022211HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022212HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TCGA Plot Options
Drug Information
GeneMTOR
DrugBank IDDB12843
Drug NameOleandrin
Target IDBE0002386
UniProt IDP42345
Regulation Typedownregulator
PubMed IDs32452588
CitationsRoth MT, Cardin DB, Borazanci EH, Steinbach M, Picozzi VJ, Rosemury A, Wadlow RC, Newman RA, Berlin J: A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Oncologist. 2020 Oct;25(10):e1446-e1450. doi: 10.1634/theoncologist.2020-0440. Epub 2020 Jul 2.
GroupsExperimental; Investigational
Direct ClassificationCardenolide glycosides and derivatives
SMILESCO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O
Pathways
PharmGKB
ChEMBLCHEMBL1075789